Company intelligence / Profile preview

Unity Technologies

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

The BEHOLD Phase 2 study demonstrated that a single injection of UBX1325 resulted in statistically significant and clinically meaningful improvement in vision through 48 weeks in patients with diabetic macular edema[4]. The ASPIRE Phase 2b study is currently evaluating UBX1325 head-to-head against aflibercept in patients with diabetic macular edema[2]. However, a previous osteoarthritis trial with UBX0101 failed in 2020, causing a 60% drop in share price[4].

Therapeutic areas: OphthalmologyRheumatology
Modalities: Small moleculeMonoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Unity Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unity Technologies.

Explore the full profile